In this study, we presented the effectiveness of the MEK inhibitor selumetinib and the PI3K/mTOR inhibitor BEZ235 alone and in combination on BRAF and BRAF + PI3K/PTEN mutant human cancer cell lines from different types of cancer (melanoma, lung and colorectal adenocarcinoma), in line with the current basket-type clinical trial design for BRAF mutant tumors [55]. The gene discussed is BRAF; the disease is colorectal adenocarcinoma.